Alxerion Biotech Corporation
Biotechnology ResearchMassachusetts, United States2-10 Employees
In collaboration with the Harvard Medical School & Massachusetts Institute of Technology’s Biomedical Engineering Center we are jointly developing Alxerion’s Novel Exosome Technologies for Drug Discovery & Delivery.
“Alxerion is the Leader in Exosome New Drug Discovery and Development Technologies”
Dr. Elazer Edelman, MD, Ph.D., F.A.C.C.
Director of the Harvard Medical School &
Massachusetts Institute of Technology’s
Biomedical Engineering Center.
Professor of Medicine at Harvard Medical School.
PERSONALIZED EXOSOME-BASED MEDICINES
The EXOKIT™ - Our core technology is a Ready-to-Use drug delivery technology which isolates, loads and re-infuses each patient’s own exosomes containing the patient’s prescribed drugs. Using the patient’s own exosomes significantly reduces dose concentrations. As such we anticipate only minimal rejection or side effects, and as EXOKIT™ delivers only the drug loaded into an exosome there is little to no free floating drugs, greatly limiting drug interaction with healthy cells and opening therapeutic treatment to large populations.
HTS-ExoPlatform™ - Our biological platforms offer extreme cost-effectiveness and highly efficient results in investigating the great untapped biodiversity of the Southern Hemisphere. We are building libraries and biobanks with this platform in cooperation with local provinces, which has resulted in the first natural exosome library containing over 10,000 exosomes and more than 30,000 small RNA and small DNA sequences and enzymes from plants, fungi, algae, microorganisms and insects.
Investors & Business Development: stevenhite@Axlerion.com
1-888-653-2347 
support@leadiq.com 
